image
Healthcare - Medical - Devices - NASDAQ - US
$ 5.73
0.563 %
$ 42.5 M
Market Cap
-3.5
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ECOR stock under the worst case scenario is HIDDEN Compared to the current market price of 5.73 USD, electroCore, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ECOR stock under the base case scenario is HIDDEN Compared to the current market price of 5.73 USD, electroCore, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ECOR stock under the best case scenario is HIDDEN Compared to the current market price of 5.73 USD, electroCore, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ECOR

image
$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.0$4.0$4.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
25.2 M REVENUE
57.09%
-12.2 M OPERATING INCOME
35.33%
-11.9 M NET INCOME
36.89%
-6.95 M OPERATING CASH FLOW
52.63%
-8.52 M INVESTING CASH FLOW
-4035.44%
8.44 M FINANCING CASH FLOW
12.72%
6.72 M REVENUE
-4.64%
-3.82 M OPERATING INCOME
-24.45%
-3.86 M NET INCOME
-19.42%
-4.36 M OPERATING CASH FLOW
-247.01%
4.5 M INVESTING CASH FLOW
998.20%
180 K FINANCING CASH FLOW
-51.48%
Balance Sheet electroCore, Inc.
image
Current Assets 16.3 M
Cash & Short-Term Investments 12 M
Receivables 1.37 M
Other Current Assets 2.96 M
Non-Current Assets 4.17 M
Long-Term Investments 0
PP&E 3.9 M
Other Non-Current Assets 274 K
58.47 %6.68 %14.48 %19.04 %Total Assets$20.5m
Current Liabilities 9.15 M
Accounts Payable 1.83 M
Short-Term Debt 361 K
Other Current Liabilities 6.96 M
Non-Current Liabilities 3.78 M
Long-Term Debt 3.78 M
Other Non-Current Liabilities 0
14.13 %2.79 %53.87 %29.20 %Total Liabilities$12.9m
EFFICIENCY
Earnings Waterfall electroCore, Inc.
image
Revenue 25.2 M
Cost Of Revenue 3.78 M
Gross Profit 21.4 M
Operating Expenses 33.6 M
Operating Income -12.2 M
Other Expenses -276 K
Net Income -11.9 M
30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)25m(4m)21m(34m)(12m)276k(12m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.97% GROSS MARGIN
84.97%
-48.30% OPERATING MARGIN
-48.30%
-47.20% NET MARGIN
-47.20%
-157.56% ROE
-157.56%
-58.06% ROA
-58.06%
-103.32% ROIC
-103.32%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis electroCore, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)(50m)(50m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -11.9 M
Depreciation & Amortization 1.26 M
Capital Expenditures 0
Stock-Based Compensation 1.87 M
Change in Working Capital 1.76 M
Others 759 K
Free Cash Flow -6.95 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets electroCore, Inc.
image
ECOR has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership electroCore, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
56.8 K USD 2
0-3 MONTHS
57.2 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
37 K USD 2
9-12 MONTHS
7. News
electroCore, Inc. (ECOR) Q1 2025 Earnings Call Transcript electroCore, Inc. (NASDAQ:ECOR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Dan Goldberger - Chief Executive Officer and Director Joshua Lev - Chief Financial Officer Conference Call Participants Tyler Bussian - Brookline Capital Operator Greetings, and welcome to the electroCore First Quarter 2025 Earnings Conference Call. At this time, all participants have been placed in a listen-only mode. seekingalpha.com - 1 month ago
ElectroCore, Inc. (ECOR) Reports Q1 Loss, Misses Revenue Estimates ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.53 per share a year ago. zacks.com - 1 month ago
electroCore Announces First Quarter 2025 Financial Results First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. globenewswire.com - 1 month ago
electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies Addition of Quell® Platform Broadens electroCore's Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets Addition of Quell® Platform Broadens electroCore's Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets globenewswire.com - 1 month ago
electroCore's Truvaga™ Now Works with the Apple Health app ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, Truvaga Plus, now works with the Apple® Health app. globenewswire.com - 1 month ago
electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025 ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of the market on Wednesday, May 7, 2025. globenewswire.com - 1 month ago
Ecora Resources expects stronger Q2 after solid start to 2025 Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) has posted what it described as a “solid start” to the year, reporting a $6 million portfolio contribution in the first quarter of 2025, down from $6.7 million in the previous quarter due to the timing of cobalt deliveries from Voisey's Bay. Chief executive Marc Bishop Lafleche said volume growth is expected to accelerate in the second quarter, with a number of key assets coming back into play. proactiveinvestors.co.uk - 1 month ago
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). globenewswire.com - 2 months ago
electroCore to Participate at the Planet MicroCap Showcase ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Planet MicroCap Showcase taking place at the Paris Hotel & Casino in Las Vegas on April 23 & 24, 2025. globenewswire.com - 2 months ago
electroCore Named One of The Americas' Fastest Growing Companies by the Financial Times ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one of “The Americas' Fastest Growing Companies 2025. globenewswire.com - 2 months ago
electroCore to Participate at the Needham Virtual Healthcare Conference ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 10, 2025. globenewswire.com - 2 months ago
electroCore Extends VA Contract for Five Years ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030. globenewswire.com - 2 months ago
8. Profile Summary

electroCore, Inc. ECOR

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 42.5 M
Dividend Yield 0.00%
Description electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Contact 200 Forge Way, Rockaway, NJ, 07866 https://www.electrocore.com
IPO Date June 22, 2018
Employees 73
Officers Mr. Mitch Deshon Vice President of Global Sales & Business Development Dr. Peter S. Staats M.B.A., M.D. Chief Medical Officer Mr. Donald Melnikoff Senior Vice President of Engineering, Regulatory & Compliance Mr. Michael Mansfield Vice President of Marketing Mr. Joshua S. Lev Chief Financial Officer Ms. Carrie Kochek Senior Director of Human Resources Mr. Brian M. Posner CPA, MBA. Consultant Dr. Thomas J. Errico M.D. Founder & Independent Director Mr. Manuel A. Marques Senior Vice President of Operations Mr. Daniel S. Goldberger Chief Executive Officer & Director